Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Contact

Board

Company Overview

Team

Corporate Governance

Corporate Directory

Values

Clinical Advisers

About Us

Video Updates

Presentations

In the News

Communication

Updates

US Shareholders

Investor FAQs

Shareholder Services

Research Reports

Reports

Announcements

Investor Fact Sheet

Top 20 Shareholders

Share Price

Investor Centre

Clinical Trial

Webinars

Home

Montserrat

Amplia Therapeutics Limited

upload.jpg

Amplia has today released topline data from its ongoing ACCENT trial, evaluating its best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane® for the treatment of advanced pancreatic cancer.

An Objective Response Rate (ORR) of 31%, significantly better when compared to chemotherapies alone (23%).

An excellent tolerability profile with adverse events being very similar in type and occurrence to those observed for the chemotherapies alone

Durability of response is excellent with 7 patients having stayed on trial for >12 months. At data cut-off 17 patients remained on trial.

Median Progression Free Survival (PFS) of 7.6 months, two months better than previously reported for chemotherapy alone. Importantly, this is also superior to the PFS obtained with the more aggressive, but less well tolerated, FOLFIRINOX chemotherapy.

Amplia CEO and MD Dr Chris Burns commented:

“The data from the ACCENT trial of narmafotinib combined with chemotherapy continues to out-perform chemotherapy alone across a number of measures. A PFS of 7.6 months at this interim stage of the trial is a significant improvement on existing chemotherapy regimes. We will provide further updates on the data as the trial matures.”

Amplia releases topline data from ACCENT Trial